You are here

Our science / Clinical Trials / Find a Trial / NCT00858143

Non Interventional Study For Patients Treated With Somavert®

Back to Search Print Save as PDF Bookmark Trial

NCT00858143

Last updated on April 10, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Acromegaly
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects with diagnosed acromegaly who were already being treated with Somavert® or
were to start treatment with Somavert® were included in the study.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects treated with an investigational drug for treatment of acromegaly.

- Subjects with symptoms such visual field loss, cranial nerve palsies or intracranial
hypertension, indicating need for surgery.

- Women who were pregnant or lactating.

NCT00858143
Pfizer
Completed
Non Interventional Study For Patients Treated With Somavert®

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Acromegaly
Non Interventional Study For Patients Treated With Somavert®
NCT00858143
All Genders
Acromegaly
Long Term Use of Pegvisomant For A Regulatory Post Marketing Commitment Plan
NCT00658879
All Genders
Acromegaly
Canadian Pegvisomant Compassionate Study In Acromegalic Patients
NCT00151437
All Genders
Acromegaly
Pegvisomant And Sandostatin LAR Combination Study
NCT00068029
All Genders
18+
Years
Multiple Sites
Non Interventional Study For Patients Treated With Somavert®
German Non Interventional Study For Patients Treated With Somavert®
This open-label, national, prospective, observational, non-interventional, multi-center, post marketing surveillance study was performed in order to examine the efficacy and safety of Somavert® in treatment of subjects with acromegaly and its effects on acromegaly related co-morbidities.
Non probability samples
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
Serum
Non-Probability Sample
Subjects with diagnosed acromegaly who were already being treated with Somavert® or were to start treatment with Somavert® were included in the study.
Acromegaly
Other: Non Interventional Observation
Post marketing surveillance study = prospective, non-interventional observation of the use of Somavert®
1
Intervention: Other: Non Interventional Observation
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
311
January 2008
January 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects with diagnosed acromegaly who were already being treated with Somavert® or were to start treatment with Somavert® were included in the study.

Exclusion Criteria:

  • Subjects treated with an investigational drug for treatment of acromegaly.
  • Subjects with symptoms such visual field loss, cranial nerve palsies or intracranial hypertension, indicating need for surgery.
  • Women who were pregnant or lactating.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00858143
A6291014
Yes
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
March 2009

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now